BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med Hypotheses 2020;144:110005. [PMID: 32575019 DOI: 10.1016/j.mehy.2020.110005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 2021;320:L257-65. [PMID: 33355522 DOI: 10.1152/ajplung.00238.2020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
2 Seifirad S, Alquran L. Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. Front Med (Lausanne) 2020;7:625440. [PMID: 33585519 DOI: 10.3389/fmed.2020.625440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia (Nathan) 2021;13:14. [PMID: 34872623 DOI: 10.1186/s41479-021-00092-9] [Reference Citation Analysis]
4 Gatti M, De Ponti F. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 2021;13:302. [PMID: 33668969 DOI: 10.3390/pharmaceutics13030302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Li Y, Wu J, Wang S, Li X, Zhou J, Huang B, Luo D, Cao Q, Chen Y, Chen S, Ma L, Peng L, Pan H, Travis WD, Nie X. Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID‐19 pneumonia in Wuhan, China. Histopathology 2021;78:542-55. [DOI: 10.1111/his.14249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
6 Sgalla G, Comes A, Lerede M, Richeldi L. COVID-related fibrosis: insights into potential drug targets. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34842488 DOI: 10.1080/13543784.2021.2010188] [Reference Citation Analysis]
7 Wang L, Balmat TJ, Antonia AL, Constantine FJ, Henao R, Burke TW, Ingham A, McClain MT, Tsalik EL, Ko ER, Ginsburg GS, DeLong MR, Shen X, Woods CW, Hauser ER, Ko DC. An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility. medRxiv 2020:2020. [PMID: 33398303 DOI: 10.1101/2020.12.20.20248572] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, Ribeiro SM, Baldi BG. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med 2021;15:791-803. [PMID: 33902377 DOI: 10.1080/17476348.2021.1916472] [Reference Citation Analysis]
9 Samantaray A, Johnson E, Kumar N, Mehdiratta L. COVID-19: A game of drugs, vaccines, hope and… death! Indian J Anaesth 2021;65:434-8. [PMID: 34248185 DOI: 10.4103/ija.ija_508_21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Fadista J, Kraven LM, Karjalainen J, Andrews SJ, Geller F, Baillie JK, Wain LV, Jenkins RG, Feenstra B; COVID-19 Host Genetics Initiative. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. EBioMedicine 2021;65:103277. [PMID: 33714028 DOI: 10.1016/j.ebiom.2021.103277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tandon S, Aggarwal A, Jain S, Shukla S, Chaudhary S. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19. Protein J 2020;39:631-43. [PMID: 33034824 DOI: 10.1007/s10930-020-09921-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Vitiello A, Pelliccia C, Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy.SN Compr Clin Med. 2020;1-4. [PMID: 32875276 DOI: 10.1007/s42399-020-00487-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
13 Wang L, Balmat TJ, Antonia AL, Constantine FJ, Henao R, Burke TW, Ingham A, McClain MT, Tsalik EL, Ko ER, Ginsburg GS, DeLong MR, Shen X, Woods CW, Hauser ER, Ko DC. An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility. Genome Med 2021;13:83. [PMID: 34001247 DOI: 10.1186/s13073-021-00904-z] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Han M, Song Y, Liu S, Lu X, Su L, Liu M, Zhu X, Sun K, Lu Y, Wang A. Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022;13:882678. [DOI: 10.3389/fphar.2022.882678] [Reference Citation Analysis]
15 Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells 2021;10:206. [PMID: 33494237 DOI: 10.3390/cells10020206] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
16 Kunal S, Madan M, Tarke C, Gautam DK, Kinkar JS, Gupta K, Agarwal R, Mittal S, Sharma SM. Emerging spectrum of post-COVID-19 syndrome. Postgrad Med J 2021:postgradmedj-2020-139585. [PMID: 34880080 DOI: 10.1136/postgradmedj-2020-139585] [Reference Citation Analysis]
17 Vitiello A, Ferrara F. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 2021;38:S129-30. [PMID: 33687000 DOI: 10.4103/lungindia.lungindia_803_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Corrie L, Muzaffar-ur-rehman M, Kukatil L, Manasa D, Shirisha A. Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters? CRMR 2021;17:8-12. [DOI: 10.2174/1573398x17666210304100043] [Reference Citation Analysis]
19 Acat M, Yildiz Gulhan P, Oner S, Turan MK. Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. Int J Clin Pract 2021;:e14961. [PMID: 34624155 DOI: 10.1111/ijcp.14961] [Reference Citation Analysis]
20 Bellanti F, Lo Buglio A, Vendemiale G. Redox Homeostasis and Immune Alterations in Coronavirus Disease-19. Biology (Basel) 2022;11:159. [PMID: 35205026 DOI: 10.3390/biology11020159] [Reference Citation Analysis]
21 Oke AS, Bada OI, Rasaq G, Adodo V. Mathematical analysis of the dynamics of COVID-19 in Africa under the influence of asymptomatic cases and re-infection. Math Methods Appl Sci 2021. [PMID: 34908633 DOI: 10.1002/mma.7769] [Reference Citation Analysis]
22 Kunnumakkara AB, Rana V, Parama D, Banik K, Girisa S, Henamayee S, Thakur KK, Dutta U, Garodia P, Gupta SC, Aggarwal BB. COVID-19, cytokines, inflammation, and spices: How are they related? Life Sci 2021;:119201. [PMID: 33607159 DOI: 10.1016/j.lfs.2021.119201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Kumar A, Sharma A, Tirpude NV, Sharma S, Padwad YS, Kumar S. Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacol. [DOI: 10.1007/s10787-021-00903-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Murugan C, Ramamoorthy S, Kuppuswamy G, Murugan RK, Sivalingam Y, Sundaramurthy A. COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. Int J Biol Macromol 2021:S0141-8130(21)02301-1. [PMID: 34710479 DOI: 10.1016/j.ijbiomac.2021.10.144] [Reference Citation Analysis]